For Immediate Release
Chicago, IL – July 7, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: salesforce.com, inc. (
CRM Quick Quote CRM - Free Report) , Thermo Fisher Scientific Inc. ( TMO Quick Quote TMO - Free Report) , Royal Dutch Shell plc ( RDS.A Quick Quote RDS.A - Free Report) , Citigroup Inc. ( C Quick Quote C - Free Report) and Starbucks Corporation ( SBUX Quick Quote SBUX - Free Report) . Here are highlights from Tuesday’s Analyst Blog: Top Stock Reports for salesforce, Thermo Fisher and Royal Dutch Shell
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including salesforce.com, Thermo Fisher Scientific and Royal Dutch Shell. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
salesforce have underperformed the Zacks Computer Software industry in the year-to-date period (+11.6% vs. +21.7%). The Zacks analyst believes that the company is benefiting from a robust demand environment as customers are undergoing a major digital transformation. The rapid adoption of its cloud-based solutions has been driving demand for its products.
Furthermore, the recent deal to acquire Slack would position the company to be a leader in enterprise team collaboration solution space and better compete with Microsoft’s Teams product. However, unfavorable currency fluctuations along with increasing investments in international expansions and data centers are an overhang on near-term profitability.
) read the full research report on salesforce here >>> Thermo Fisher’s shares have gained +10.2% over the past three months against the Zacks Medical Instruments industry’s gain of +11.1%. The Zacks analyst believes that Thermo Fisher is expanding its inorganic growth profile with several takeovers including Advanced Bioprocessing buyout from BD and Patheon.
The company delivered an outstanding performance in the first quarter of 2021 on the back of accelerated growth in its Base business. Further, in terms of end market, the pharma and biotech segments also registered impressive growth. However, the pandemic has massively disrupted the global supply chain. Foreign currency fluctuations and competitive landscape are other major downsides.
) read the full research report on Thermo Fisher here >>>
Royal Dutch Shell have gained +4.1% in the last six months against the Zacks International Integrated Oil industry’s gain of +22.6%. The Zacks analyst believes that with LNG demand likely to rise significantly in the near-to-medium term, Shell’s position as a major supplier of LNG should help the company meet the fuel’s growing demand, thereby improving cash flow.
Meanwhile, the company is also making solid progress toward the transition to a renewable energy-focused future. However, Shell hasn’t been immune to the coronavirus-induced energy downturn and is also facing some headwinds on the production front. There are also worries over the company’s poor reserve replacement ratio of just 65%.
) read the full research report on Royal Dutch Shell here >>>
Other noteworthy reports we are featuring today include Citigroup and Starbucks.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.